Shares of Teva Pharmaceuticals Ltd. TEVA,
gained 2.7% in pre-sale trading on Wednesday after the drug dealer expected expectations for revenue and a change in earnings per share in the last quarter of 2020. There was a loss of $ 150 million, or 14 cents per share at Teva, in the fourth quarter of 2020, compared with a loss of $ 110 million, or 10 cents per share, in the same quarter a year ago. He had earned earnings per share of 68 cents, against a FactSet consensus of 64 cents per share. Teva’s revenue was $ 4.45 billion for the quarter, compared to $ 4.47 billion in the fourth quarter of 2019. FactSet’s consensus was $ 4.43 billion. Its North American sex drug industry saw sales of $ 1.2 billion in the fourth quarter of 2020, down from $ 1.1 billion in the same quarter in 2019. Teva said it expects revenue of $ 16.4 billion. brought in $ 16.8 billion in 2021 and led EPS for $ 2.50 to $ 2.70 for the year. Teva has been in reversal mode under Teva CEO Kåre Schultz. “We are still on track to repay our debt and meet our long-term financial targets,” he said in a press release on Wednesday. The company’s short-term debt was $ 3.2 billion as from Deb.31, up from $ 2.3 billion from Deb.31, 2019. Teva stock has gained 8.2% over the past 12 months, and the S&P 500 SPX more broadly,
up 17.5%.